The Project Grant award R43NS135837, funded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, aims to develop an optimized formulation of the positive allosteric modulator EPGN2325 for intravenous administration to treat acute ischemic stroke and support post-stroke recovery. The $550,864 award to Epigen Biosciences Inc., a drug discovery company with experience in federal research grants, will fund studies to: 1) develop a clinically-relevant formulation of EPGN2325 suitable for intravenous use in acute stroke and recovery phases, and 2) determine the pharmacokinetic and pharmacodynamic profile of the optimized EPGN2325 formulation. These studies are intended to provide data to support the potential development of EPGN2325 as an investigational new drug for stroke treatment.
Generated 1/28/25, 7:27 AM